Nikhil Lalwani

Nikhil Lalwani is a declared insider of ANI Pharmaceuticals Inc (chief executive), with filings sourced from SEC (Form 4). Between 8 September 2020 and 15 October 2026, the trades on record add up to 45 filings.

On the open market, the record shows 1 purchase worth €181k and 11 sales worth €14.5M. Sales outweigh purchases by €14.3M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 31 share grants and 2 option exercises. In 2026 alone, the filings show no purchases and 3 sales.

Most recently, on 16 October 2026, the filings show an open-market sale worth €346k in ANI Pharmaceuticals Inc. The last purchase on record was published on 23 March 2022, which is 1,676 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.